What is Spyre Therapeutics, Inc.'s stock-based comp?

Spyre Therapeutics, Inc. (SYRE) reported stock-based comp of $12.81M in Q1 2026.

How has Spyre Therapeutics, Inc.'s stock-based comp changed year-over-year?

Spyre Therapeutics, Inc.'s stock-based comp increased by 44.6% year-over-year, from $8.86M to $12.81M.

What is the long-term trend for Spyre Therapeutics, Inc.'s stock-based comp?

Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s stock-based comp has grown at a 47.1% compound annual growth rate (CAGR), from $8.04M to $37.61M.

Spyre Therapeutics, Inc. SYRE Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

Eli LillyLLY

$161M+4.5%

PfizerPFE

$272M+60.0%

Johnson & JohnsonJNJ

$300M+4.2%

Merck & Co.MRK

$185M-5.1%

AbbVieABBV

$444M+8.3%

Segments

By segment

See full

Reportable Segment$12.81M+44.6%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s stock-based comp?: Spyre Therapeutics, Inc. (SYRE) reported stock-based comp of $12.81M in Q1 2026.
How has Spyre Therapeutics, Inc.'s stock-based comp changed year-over-year?: Spyre Therapeutics, Inc.'s stock-based comp increased by 44.6% year-over-year, from $8.86M to $12.81M.
What is the long-term trend for Spyre Therapeutics, Inc.'s stock-based comp?: Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s stock-based comp has grown at a 47.1% compound annual growth rate (CAGR), from $8.04M to $37.61M.